Pharmaceutical Control of the
Human Microbiome

National Cancer Institute Awards Phase 1 SBIR Contract to Symberix

September 2016

Symberix received a one-year Phase I Small Business Innovation Research (SBIR) contract from the National Cancer Institute beginning September 2016. The contract funds new research aimed at identifying the relevant bacterial GUS enzyme that metabolizes two targeted anti-cancer drugs associated with high incidences of lower GI toxicities.

For more information on the SBIR program, click here: https://sbir.cancer.gov/about

 


Back to News